A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)

OBJECTIVE: Abiraterone acetate has been approved in >70 countries for chemotherapy-naïve metastatic castration-resistant prostate cancer patients. Efficacy and safety of abiraterone acetate (1000 mg/once daily) with prednisolone (5 mg/twice daily) in chemotherapy-naïve Japanese patients with meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubara, Nobuaki, Uemura, Hirotsugu, Satoh, Takefumi, Suzuki, Hiroyoshi, Nishiyama, Tsutomu, Uemura, Hiroji, Hashine, Katsuyoshi, Imanaka, Keiichiro, Ozono, Seiichiro, Akaza, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243579/
https://www.ncbi.nlm.nih.gov/pubmed/25320340
http://dx.doi.org/10.1093/jjco/hyu149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243579/
https://www.ncbi.nlm.nih.gov/pubmed/25320340
http://dx.doi.org/10.1093/jjco/hyu149

Ejemplares similares